(Updated - May 7, 2019 5:07 PM EDT)

REGENXBIO Inc. (NASDAQ: RGNX) today an update to its Phase I/IIa ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Regenxbio (RGNX) Misses Q1 EPS by 3cMay 7, 2019 5:01 PM REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMDMay 7, 2019 4:06 PM